Document 0664
 DOCN  M95A0664
 TI    Protease inhibitor studies enrolling. 
 DT    9510
 SO    Treat Rev. 1995 Mar/Apr;(no 17):3. Unique Identifier : AIDSLINE
       AIDS/95700319
 AB    The protease enzyme is essential for HIV to make copies of itself. So
       far, research has failed to find a protease inhibitor that works against
       HIV. It is believed that, regardless of what type of protease inhibitor
       someone takes, it will need to be supplemented with other anti-HIV
       drugs. Three protease inhibitors have thus far been found to be safe,
       although long-term effects are unknown. These drugs are saquinavir,
       ABT-538, and L-735,524 produced by Hoffman-LaRoche, Abbott, and Merck
       respectively. Clinical trials of saquinavir are promising but it has not
       been shown to be the knock-out drug needed. ABT-538 has high
       bioavailability, but studies are showing it can cause liver and eye
       damage. L-735,524 studies are showing that resistance develops quite
       quickly. Future studies at higher doses are expected. To obtain
       information on protease studies currently looking for participants,
       contact The Network. Information on other approved, alternative, and
       experimental drugs is also available.
 DE    Clinical Trials  HIV Infections/*DRUG THERAPY  HIV Protease
       Inhibitors/*THERAPEUTIC USE  Human  Pyridines/*THERAPEUTIC USE
       NEWSLETTER ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).